PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22534255-17	2012	These findings suggest that gemigliptin may require a dose adjustment when concurrently administered with drugs that alter CYP3A4 activity.	LC15-0444	28-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	123-129	
24304170-13	2014	CYP3A4 was identified as the dominant CYP isozyme converting gemigliptin to LC15-0636 in recombinant CYP/FMO enzymes.	LC15-0444	61-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6